iCo Therapeutics (ICO) Stock Price, News & Analysis

Company Overview

iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat ocular and infectious diseases. Its in-licensed drug candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat ulcerative colitis and bullous pemphigoid; and Oral AmpB Delivery System, an oral formulation of Amphotericin B that is in Phase 1b clinical trial for the treatment of systemic fungal and parasitic infections. The company was incorporated in 2005 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: C$0.10 to C$0.11
• 50-Day Range: C$0.11 to C$0.11
• 52-Week Range: C$0.02 to C$0.16
• Volume: 1.31 million shs
• Average Volume: 3.16 million shs
• Market Capitalization: C$951.83 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: CVE:ICO
• CIK: N/A
• Web: www.icotherapeutics.com
• Phone: +1-604-6029414
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.14
• Quick Ratio: 1.12

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.01 per share
• Price / Cash Flow: 8.75
• Book Value: C$0.00 per share
• Price / Book: 105.00

Miscellaneous

• Outstanding Shares: 9,065,000
• Free Float: N/A
• Market Cap: C$951.83 thousand
• Optionable: Not Optionable
• Beta: N/A